TY - JOUR
T1 - Levels of omega-3 fatty acid in serum phospholipids and depression in patients with lung cancer
AU - Kobayakawa, M.
AU - Yamawaki, S.
AU - Hamazaki, K.
AU - Akechi, T.
AU - Inagaki, M.
AU - Uchitomi, Y.
N1 - Funding Information:
This work was supported in part by the Third-Term Comprehensive 10-Year Strategy for Cancer Control and Research, Japanese Ministry of Health, Labour, and Welfare. Makoto Kobayakawa is an awardee of the Research Resident Fellowship of the Foundation
PY - 2005/12/12
Y1 - 2005/12/12
N2 - Previous studies suggested that omega-3 fatty acids (FAs) have therapeutic effects against depression, but there is no evidence in the oncological setting. Our preliminary study reported the association between lower omega-3 FA intake and occurrence of depression in lung cancer patients. To explore the association further, the present study examined whether depression was associated with lower levels of omega-3 FAs in serum phospholipids. A total of 717 subjects in the Lung Cancer Database Project were divided into three groups by two cutoff points of the Hospital Anxiety and Depression Scale depression subscale (HADS-D). In all, 81 subjects of the nondepression and minor depression groups (HADS-D < 5 and 5 ≤ HADS-D ≤ 10, respectively) were selected to match with 81 subjects of the major depression group (HADS-D > 10) for age, gender, clinical stage, and performance status. Fatty acids were assayed by gas chromatography and compared among the three matched groups. There were no differences between the major depression group and nondepression group in any FAs. The minor depression group had higher mean levels of docosahexaenoic acid (mean ± s.d. (%), nondepression: 7.40 ± 1.54; minor depression: 7.90 ± 1.40; major depression: 7.25 ± 1.52, P = 0.017). These results suggested that serum FAs are associated with minor, but not major, depression in lung cancer patients.
AB - Previous studies suggested that omega-3 fatty acids (FAs) have therapeutic effects against depression, but there is no evidence in the oncological setting. Our preliminary study reported the association between lower omega-3 FA intake and occurrence of depression in lung cancer patients. To explore the association further, the present study examined whether depression was associated with lower levels of omega-3 FAs in serum phospholipids. A total of 717 subjects in the Lung Cancer Database Project were divided into three groups by two cutoff points of the Hospital Anxiety and Depression Scale depression subscale (HADS-D). In all, 81 subjects of the nondepression and minor depression groups (HADS-D < 5 and 5 ≤ HADS-D ≤ 10, respectively) were selected to match with 81 subjects of the major depression group (HADS-D > 10) for age, gender, clinical stage, and performance status. Fatty acids were assayed by gas chromatography and compared among the three matched groups. There were no differences between the major depression group and nondepression group in any FAs. The minor depression group had higher mean levels of docosahexaenoic acid (mean ± s.d. (%), nondepression: 7.40 ± 1.54; minor depression: 7.90 ± 1.40; major depression: 7.25 ± 1.52, P = 0.017). These results suggested that serum FAs are associated with minor, but not major, depression in lung cancer patients.
KW - Lung cancer
KW - Major depression
KW - Minor depression
KW - Omega-3 fatty acid
KW - Serum phospholipids
UR - http://www.scopus.com/inward/record.url?scp=28644443767&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=28644443767&partnerID=8YFLogxK
U2 - 10.1038/sj.bjc.6602877
DO - 10.1038/sj.bjc.6602877
M3 - Article
C2 - 16306875
AN - SCOPUS:28644443767
SN - 0007-0920
VL - 93
SP - 1329
EP - 1333
JO - British Journal of Cancer
JF - British Journal of Cancer
IS - 12
ER -
